Board of Biocon Biologics allots OCDs aggregating Rs 1125 cr

On 09 December 2020

The Board of Biocon Biologics (BBL) on 09 December 2020 has approved the allotment of 1,125 Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) at face value of Rs. 1 crore each aggregating to Rs. 1,125 crore of BBL to the Investor i.e. Goldman Sachs India AIF Scheme - 1, a scheme setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management.

Powered by Capital Market - Live News